how her2+breast cancer subtypes differ(and why some respond better2 targeted therapy

[Lani]

I have previously commended Maurizio Scaltriti, who did the original preclinical research showing the supersynergism of herceptin plus lapatinib --the basis for the neoadjuvant studies and for the combined treatment many of you have benefitted from


http://www.readcube.com/articles/10....4269?locale=en